CTMX Earnings Prediction
The chart below shows how CTMX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CTMX sees a -4.12% change in stock price 10 days leading up to the earnings, and a -1.10% change 10 days following the report. On the earnings day itself, the stock moves by +1.55%. This data can give you a slight idea of what to expect for the next quarter's release.
CTMX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
--
--
--
No Data Available
CTMX Earnings Analysis
CytomX Therapeutics Inc Corporation (CTMX.O) Earnings Conference Call
Positive
Earnings Per Share Beat: CytomX Therapeutics, Inc. reported an EPS of $0.22, exceeding expectations of $-0.23, indicating strong financial performance.
Therapeutic Pipeline Advancement: The company advanced two new programs, CX-2051 and CX-801, into the clinic, showcasing progress in their therapeutic pipeline.
First-in-Class ADC for Colorectal Cancer: CX-2051 is a first-in-class ADC targeting EPCAM, addressing a significant unmet need in colorectal cancer with a large patient population.
Next-Generation Immunotherapy Development: CX-801, a masked version of interferon alpha, is showing promise as a next-generation targeted immunotherapy, with plans for combination therapy with KEYTRUDA in 2025.
Milestone Payment Achievement: CytomX achieved a $5 million milestone payment in their collaboration with STELLUS, reflecting successful partnerships and progress in their research collaborations.
Strong Revenue Increase: Total revenue for 2024 was $138.1 million, an increase from $101.2 million in 2023, driven by collaborations with BMS, Moderna, and others, indicating strong revenue growth.
Cash Runway Extension: The company ended 2024 with $100.6 million in cash, extending their cash runway into Q2 of 2026, which supports ongoing operations and clinical trials.
Negative
Earnings Beat, Cash Decline: Despite beating earnings expectations with an EPS of $0.22 compared to the expected $-0.23, the company ended 2024 with significantly reduced cash reserves of $100.6 million, down from $174.5 million at the end of 2023, raising concerns about financial stability.
Rising Operating Expenses: Operating expenses increased to $113.1 million in 2024 from $107.7 million in 2023, primarily due to a $5 million milestone payment for CX-2051, indicating rising costs associated with their clinical programs.
Metastatic Colorectal Cancer Challenges: The company acknowledged that the current standard of care for metastatic colorectal cancer (CRC) remains inadequate, with low to mid-single-digit objective response rates and a median progression-free survival of only two to four months, highlighting the challenges they face in the market.
Project Development Shift: CytomX has decided not to continue the development of CX-904 in collaboration with Amgen, which may reflect setbacks in their T cell engager program and a need to refocus resources on more promising projects.
Cash Guidance Limitations: The company’s cash guidance does not assume any additional milestones from existing collaborations or new business development, which could limit future revenue growth and operational flexibility.
CTMX FAQs
How does CTMX typically perform around its earnings report dates?
Is CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CTMX Earning Call Sentiment
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2024 Earnings Call Transcript
CTMX.O
7.71%Positive
The earnings call presents strong financial performance with a positive EPS surprise and increased revenue. Despite increased expenses, the company's partnerships and milestone achievements suggest future growth. The Q&A section shows management's optimism and transparency about clinical developments, although there were some unclear responses. The cash runway until 2026 and optimistic guidance further support a positive sentiment. The absence of major negative factors and the company's strategic collaborations indicate a likely stock price increase in the near term.
